CN107530379A - 用于治疗肥胖症和2型糖尿病(t2d)的胰腺内分泌祖细胞疗法 - Google Patents

用于治疗肥胖症和2型糖尿病(t2d)的胰腺内分泌祖细胞疗法 Download PDF

Info

Publication number
CN107530379A
CN107530379A CN201680024439.5A CN201680024439A CN107530379A CN 107530379 A CN107530379 A CN 107530379A CN 201680024439 A CN201680024439 A CN 201680024439A CN 107530379 A CN107530379 A CN 107530379A
Authority
CN
China
Prior art keywords
cells
population
pancreatic endocrine
subject
progenitor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680024439.5A
Other languages
English (en)
Chinese (zh)
Inventor
蒂莫西·J·基弗
詹尼弗·E·布鲁因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peiteni Resources Ltd
Original Assignee
Peiteni Resources Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peiteni Resources Ltd filed Critical Peiteni Resources Ltd
Publication of CN107530379A publication Critical patent/CN107530379A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680024439.5A 2015-03-11 2016-03-11 用于治疗肥胖症和2型糖尿病(t2d)的胰腺内分泌祖细胞疗法 Pending CN107530379A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131540P 2015-03-11 2015-03-11
US62/131,540 2015-03-11
PCT/CA2016/000072 WO2016141460A1 (en) 2015-03-11 2016-03-11 Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Publications (1)

Publication Number Publication Date
CN107530379A true CN107530379A (zh) 2018-01-02

Family

ID=56879832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680024439.5A Pending CN107530379A (zh) 2015-03-11 2016-03-11 用于治疗肥胖症和2型糖尿病(t2d)的胰腺内分泌祖细胞疗法

Country Status (7)

Country Link
US (2) US10772917B2 (enExample)
EP (1) EP3268016B1 (enExample)
JP (1) JP6847044B2 (enExample)
CN (1) CN107530379A (enExample)
AU (1) AU2016228894B2 (enExample)
CA (1) CA2979293C (enExample)
WO (1) WO2016141460A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072A (zh) * 2020-03-09 2020-07-14 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951136B2 (en) 2017-12-12 2024-04-09 The Regents Of The University Of California Preservation of pancreatic islet grafts in the extrahepatic space
AU2019208634B2 (en) 2018-01-18 2024-06-13 Daiichi Sankyo Company, Limited Dihydroindolizinone derivative
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US12435315B2 (en) 2019-05-22 2025-10-07 The Cleveland Clinic Foundation Generating dorsal foregut, and anterior domain, endoderm cells
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
CN102016582A (zh) * 2006-10-31 2011-04-13 国家干细胞控股公司 鉴别、分离和利用来自成人胰腺的内分泌祖细胞的方法
CN102387795A (zh) * 2009-02-13 2012-03-21 贝林格尔.英格海姆国际有限公司 包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
CN103052393A (zh) * 2010-08-12 2013-04-17 詹森生物科技公司 用胰腺内分泌前体细胞治疗糖尿病

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
BR0213805A (pt) * 2001-11-09 2005-08-16 Artecel Sciences Inc Células estromais derivadas de tecido adiposo para diferenciação endócrina do pâncreas e usos das mesmas
AU2003231864A1 (en) * 2002-05-24 2003-12-12 University Of Alberta Treatment for diabetes
EP1539928A4 (en) * 2002-09-06 2006-09-06 Amcyte Inc POSIOTIVE PANCREATIC ENDOCRINE PROGENITOR CELLS CD56 IN ADULT HUMAN BEINGS
AU2004252571C1 (en) 2003-06-27 2012-03-01 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
JP2006149380A (ja) * 2004-10-27 2006-06-15 Kobe Univ 遺伝子改変動物の新規用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
EP2089005B1 (en) * 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
MX2010005805A (es) 2007-11-27 2010-06-09 Lifescan Inc Diferenciacion de celulas madre embrionarias humanas.
WO2009137844A2 (en) * 2008-05-09 2009-11-12 Vistagen Therapeutics, Inc. Pancreatic endocrine progenitor cells derived from pluripotent stem cells
CA2778817A1 (en) 2009-10-29 2011-05-19 Janssen Biotech, Inc. Pluripotent stem cells
WO2011160066A1 (en) * 2010-06-17 2011-12-22 Regents Of The University Of Minnesota Production of insulin producing cells
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1589904A (zh) * 2003-09-01 2005-03-09 北京大学 造血干细胞动员剂制备治疗糖尿病药物的用途
CN102016582A (zh) * 2006-10-31 2011-04-13 国家干细胞控股公司 鉴别、分离和利用来自成人胰腺的内分泌祖细胞的方法
CN102387795A (zh) * 2009-02-13 2012-03-21 贝林格尔.英格海姆国际有限公司 包含dpp-4抑制剂(利拉列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
CN103052393A (zh) * 2010-08-12 2013-04-17 詹森生物科技公司 用胰腺内分泌前体细胞治疗糖尿病

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALIREZA REZANIA 等: "Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells", 《NATURE BIOTECHNOLOGY》 *
P. A. HALBAN 等: "Cell therapy for type 2 diabetes: is it desirable and can we get it?", 《DIABETES, OBESITY AND METABOLISM》 *
STEPHANIE ALESKOW STEIN等: "A review of the efficacy and safety of oral antidiabetic drugs", 《EXPERT OPINION ON DRUG SAFETY》 *
蔡威 主编: "《现代营养学》", 31 December 2010, 复旦大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110585242A (zh) * 2019-10-15 2019-12-20 南通大学 多系分化持续应激细胞的应用、治疗糖尿病的药物及其制备方法
CN111411072A (zh) * 2020-03-09 2020-07-14 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Also Published As

Publication number Publication date
WO2016141460A1 (en) 2016-09-15
EP3268016B1 (en) 2021-04-28
EP3268016A1 (en) 2018-01-17
US20210015872A1 (en) 2021-01-21
EP3268016A4 (en) 2018-12-12
JP2018507889A (ja) 2018-03-22
AU2016228894B2 (en) 2021-03-04
CA2979293A1 (en) 2016-09-15
US20180055890A1 (en) 2018-03-01
JP6847044B2 (ja) 2021-03-24
AU2016228894A1 (en) 2017-11-02
CA2979293C (en) 2022-01-04
US10772917B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
US11827905B2 (en) SC-beta cells and compositions and methods for generating the same
US20210015872A1 (en) Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)
KR102167396B1 (ko) 줄기세포용 배양 배지
Kassem et al. Exendin-4 enhances the differentiation of Wharton’s jelly mesenchymal stem cells into insulin-producing cells through activation of various β-cell markers
CZ2004696A3 (cs) Endokrinní pankreatická diferenciace buněk stromatu odvozených z adipózní tkáně a její použití
Navarro-Tableros et al. Islet-like structures generated in vitro from adult human liver stem cells revert hyperglycemia in diabetic SCID mice
KR20200087201A (ko) 섬세포 제조 조성물 및 사용 방법
Kim et al. Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells
CN118678961A (zh) 用于糖尿病的细胞疗法
WO2014129628A1 (ja) 多能性幹細胞から膵ランゲルハンス島を製造する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200413

Address after: Great temperature

Applicant after: CCS Venture Capital Co., Ltd

Address before: Washington State

Applicant before: THE UNIVERSITY OF BRITISH COLUMBIA

TA01 Transfer of patent application right